Polivy (polatuzumab vedotin)

Polivy is an anti-CD79b antibody-drug conjugate (ADC). Polivy is currently approved in combination with bendamustine plus rituximab in the US for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, who have received at least two prior therapies, and in Europe for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for a haematopoietic stem cell transplant. Polivy in combination with bendamustine plus rituximab is also approved in five other countries.